TABLE 1.
Literature review of the use of sentinel lymph nodes biopsy in vulvar cancer
| Authors | Years | Study type | Patients (groins) | Mapping method | Median FU | Groin recurrence (%) | Outcome in SLN negative patients (%, 95% CI) |
|---|---|---|---|---|---|---|---|
| van der Zee (GROINSS‐V study) 37 | 2008 | Prospective | 403 (623) | R + B | 35 (2–87) |
6/259 (2.3) unifocal disease; 8/276 (3) including multifocal disease |
3‐year DSS (97) |
| Oonk 42 | 2010 | Prospective | 403 | R + B | 120 | 11 (2.7) | NA |
| Levenback (GOG 173) 41 | 2012 | Prospective | 452 (772) | R + B | NA | NA | NA |
| Woelber 44 | 2013 | Retrospective |
Primary SLN group = 74/106 Secondary SLN group = 32/106 |
R | 33 (3–118) |
Primary SLN group = 4/74 (5.4); Secondary SLN group = 0 |
Primary SLN group = 3‐year DFS (72.5) Secondary SLN group = 3‐year DFS (92.5) |
| Robison 45 | 2014 | Prospective | 86 | R + B | 58 | 4/86 (4.7) | NA |
| Te Grootenhuis 46 | 2015 | Prospective | 377 | R + B | 105 (0–179) | 6/253 (2.5) unifocal disease |
5‐year DSS (93.5) 10‐year DSS (90.8) 5‐year OS |
| Klapdor 47 | 2017 | Retrospective | 772 | R or B | 33 (0–156) | 2/69 (2.9) |
3‐year PFS (82.7; 72.3–92.7) 3‐year OS (92.7; 85.7–99.7) |
| Nica 48 | 2019 | Retrospective | 159 (245) | R or R + B | 31 | 6/120 (5) |
1‐year PFS (90) 5‐year PFS (80) |
Abbreviations: B, blue dye; DFS, disease‐free survival; DSS, disease‐specific survival; OS, overall survival; PFS, progression‐free survival; R, radiotracer.